ENP Newswire -
Release date- 21012014 -
This award continues
'There is an industry-wide need for new predictive tools that will assess the safety of drug compounds much earlier in the drug-development process,' said Dr. Watkins, who also chairs the U.S. Drug-Induced Liver Injury Network, funded by the
'Patients' susceptibility to adverse reactions appears to involve genetic makeup but is also associated with non-genetic factors, such as age, nutrition and drug interactions,' said Dr. Watkins. 'We are excited about the progress we are making in understanding this problem, and I am honored to receive the Agilent Thought Leader Award in support of our efforts.'
'Drug-induced liver injury is a primary reason why some promising new drug candidates fail during clinical development and why other drugs are pulled off the market,' said Dr.
'We are delighted with the excellent research that Hamner scientists have produced and are very pleased to now recognize Dr. Watkins as an Agilent Thought Leader,' he added. 'We believe the results of pan-omic studies of drug induced liver damage will make a significant contribution to the understanding of metabolomic, proteomic and genetic associations and lead to more certain toxicity testing in multiple markets.'
About the Agilent Thought Leader Award
The Agilent Thought Leader Award promotes fundamental scientific advances of influential thought leaders in the life sciences and chemical analysis industries. Information about previous award recipients is available at
Most Popular Stories
- Obama Administration Releases Proposal to Regulate For-Profit Colleges
- Elizabeth Vargas' Husband Marc Cohn Addresses Rumors
- Keurig Adds Peet's coffee, Alters Starbucks deal
- U.S. to Relinquish Gov't Control Over Internet
- Quiznos Files for Chapter 11
- SoCalGas Reaches Record Spend on Diversity Suppliers
- U.S. Consumer Sentiment Falls in Early March
- Vybz Kartel Convicted of Murder
- Koch Brothers Step up Anti-Obamacare Campaign
- Is Malaysian Airlines Flight 370 in Andaman Sea?